Company registration number 11751559 (England and Wales)
Radiotherapy4life Limited
Unaudited financial statements
For the year ended 30 June 2023
Radiotherapy4life Limited
Company information
Director
Prof P M Price
Company number
11751559
Registered office
4 Abbotsbury House
139 Abbotsbury Road
London
United Kingdom
W14 8EN
Accountants
DJH Mitten Clarke Manchester Limited
St George's House
56 Peter Street
Manchester
M2 3NQ
Radiotherapy4life Limited
Contents
Page
Statement of financial position
1 - 2
Notes to the financial statements
3 - 5
Radiotherapy4life Limited
Statement of financial position
As at 30 June 2023
30 June 2023
- 1 -
2023
2022
Notes
£
£
£
£
Fixed assets
Tangible assets
3
1,023
1,279
Current assets
Debtors
4
9,413
2,413
Cash at bank and in hand
14,657
55,597
24,070
58,010
Creditors: amounts falling due within one year
5
(9,693)
(43,078)
Net current assets
14,377
14,932
Total assets less current liabilities
15,400
16,211
Provisions for liabilities
(195)
(243)
Net assets
15,205
15,968
Capital and reserves
Called up share capital
1
1
Profit and loss reserves
15,204
15,967
Total equity
15,205
15,968
The director of the company has elected not to include a copy of the income statement within the financial statements.true
For the financial year ended 30 June 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
Radiotherapy4life Limited
Statement of financial position (continued)
As at 30 June 2023
30 June 2023
- 2 -
The financial statements were approved and signed by the director and authorised for issue on 9 November 2023
Prof P M Price
Director
Company Registration No. 11751559
Radiotherapy4life Limited
Notes to the financial statements
For the year ended 30 June 2023
- 3 -
1
Accounting policies
Company information
Radiotherapy4life Limited is a private company limited by shares incorporated in England and Wales. The registered office is 4 Abbotsbury House, 139 Abbotsbury Road, London, United Kingdom, W14 8EN.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
1.2
Turnover
Revenue is recognised when the Company has entitlement to the funds, it is probable that the revenue will be received and the amount can be measured reliably.
1.3
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Computer Equipment
20% on reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.4
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
These financial statements for the year ended 30 June 2023 are the first financial statements of Radiotherapy4life Limited prepared in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland. The date of transition to FRS 102 was 1 July 2021. The reported financial position and financial performance for the previous period are not affected by the transition to FRS 102.
Radiotherapy4life Limited
Notes to the financial statements (continued)
For the year ended 30 June 2023
1
Accounting policies
(Continued)
- 4 -
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
Basic financial liabilities
These financial statements for the year ended 30 June 2023 are the first financial statements of Radiotherapy4life Limited prepared in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland. The date of transition to FRS 102 was 1 July 2021. The reported financial position and financial performance for the previous period are not affected by the transition to FRS 102.
1.5
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.
Current or deferred taxation assets and liabilities are not discounted.
Current tax
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted by the balance sheet date.
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2023
2022
Number
Number
Total
1
1
Radiotherapy4life Limited
Notes to the financial statements (continued)
For the year ended 30 June 2023
- 5 -
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 July 2022 and 30 June 2023
1,999
Depreciation and impairment
At 1 July 2022
720
Depreciation charged in the year
256
At 30 June 2023
976
Carrying amount
At 30 June 2023
1,023
At 30 June 2022
1,279
4
Debtors
2023
2022
Amounts falling due within one year:
£
£
Other debtors
9,413
2,413
5
Creditors: amounts falling due within one year
2023
2022
£
£
Trade creditors
1,390
Other creditors
9,693
41,688
9,693
43,078
6
Related party transactions
During the period the company made donations of £44,083 (2022:£64,680) to Radiotherapy UK. A charity in which the director is a trustee.